Editing the trajectory of hypertrophic cardiomyopathy

References

[1] Marian AJ.Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy.Circ Res2017;121:749-70 PMCID:PMC5654557

[2] Olivotto I,Barriales-Villa R.Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2020;396:759-69

[3] Chai AC,Chemello F.Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice.Nat Med2023;29:401-11 PMCID:PMC10053064

[4] Reichart D,Wakimoto H.Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice.Nat Med2023;29:412-21 PMCID:PMC9941048

[5] Geisterfer-Lowrance AA,Conner DA.A mouse model of familial hypertrophic cardiomyopathy.Science1996;272:731-4

[6] Gaudelli NM,Rees HA.Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage.Nature2017;551:464-71 PMCID:PMC5726555

[7] Levy JM,Pendse N.Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.Nat Biomed Eng2020;4:97-110 PMCID:PMC6980783

[8] Anzalone AV,Podracky CJ.Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing.Nat Biotechnol2022;40:731-40 PMCID:PMC9117393

[9] Lebek S,Caravia XM.Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease.Science2023;379:179-85 PMCID:PMC10150399